A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers
Smoking is the greatest risk factor for upper aerodigestive cancers (thoracic or head and neck) and negatively impacts survival and other outcomes, but many patients have difficulty quitting after their diagnosis. Smoking cessation interventions for cancer patients thus far have had limited success. This is a pilot randomized controlled trial designed to determine if a new comprehensive, evidence-based smoking cessation intervention can improve quit rates for cancer patients who smoke.
Checked against the public recordLast updated Jan 17, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Interventions being studied
- Other: Comprehensive smoking cessation intervention; Behavioral: Enhanced usual care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * New diagnosis of head and neck or thoracic (including lung) cancer * Undergoing radiation at Johns Hopkins Radiation Oncology for 5 or more weeks * English-speaking and able to provide informed consent * Smoked any cigarettes in previous 14 days Exclusion Criteria: * Palliative radiation * Undergoing stereotactic radiosurgery * Pregnant or breastfeeding
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Johns Hopkins MedicineBaltimore, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2019. Always confirm current availability with the study team.